Breztri Aerosphere significantly reduced rate of moderate or severe COPD exacerbations in phase III ETHOS trial.- AstraZeneca
Full results from the positive Phase III ETHOS trial showed AstraZeneca’s triple-combination therapy Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) demonstrated a statistically significant reduction in the rate of moderate or… read more.